Alessa Therapeutics https://validator.w3.org/feed/docs/rss2.html Science Prostate Cancer Home Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, A First-Of-Its-Kind Treatment for Localized Prostate Cancer Careers Contact Clinical Trials Pipeline Alessa Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Alessa Therapeutics Announces Positive Preliminary Safety and Efficacy Data from Enolen Phase 1 Trial World-First Prostate Cancer Treatment Trialed In Tauranga Alessa Therapeutics Announces First Patient Enrolled in the Enolen Study for Localized Drug Delivery for Prostate Cancer Alessa Therapeutics Appoints Cam Gallagher as President & Chief Executive Officer Alessa Therapeutics Announces Closing $15M Seed Financing Alessa Therapeutics Announces Podium Presentation at the 2024 AUA Meeting Alessa Therapeutics Announces Poster Presentation at the 2024 EAU Meeting Alessa Therapeutics Announces First Patient Enrollment in Biolen®+RT Study with National Cancer Institute Alessa Therapeutics Announces Research Collaboration with Janssen Alessa Therapeutics Announces IND Clearance for a Study in Collaboration with the National Cancer Institute Alessa Therapeutics Announces First Patient Enrolled in Biolen-PC Study for Localized Drug Delivery for Prostate Cancer Privacy Statement (US) Alessa Therapeutics Announces First Australian Patient Enrolled in Biolen-PC Study for Localized Drug Delivery for Prostate Cancer Alessa Therapeutics is a 2020 Leadership Forum and HealthTech Showcase Finalist Opt-out preferences